Park Avenue Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Park Avenue Securities’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$656K	Sell	2,180 -616	-22%	-$186K	﹤0.01%	1164
2026 Q1	$925K	Buy	2,796 +405	+17%	+$138K	0.01%	847
2025 Q4	$951K	Sell	2,391 -340	-12%	-$150K	0.01%	832
2025 Q3	$1.25M	Buy	2,731 +646	+31%	+$263K	0.01%	787
2025 Q2	$680K	Buy	+2,085	New	+$577K	0.01%	927
2025 Q1	–	Sell	-1,368	Closed	-$322K	–	1169
2024 Q4	$322K	Buy	1,368 +538	+65%	+$141K	﹤0.01%	1260
2024 Q3	$228K	Buy	+830	New	+$216K	﹤0.01%	1295

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Park Avenue Securities's ALNY Position: Q2 2026 in Review

Park Avenue Securities reduced its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, selling an estimated $186K and leaving 2,180 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

Park Avenue Securities first reported a position in ALNY in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.25M in Q3 2025. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Park Avenue Securities held 2,180 shares of Alnylam Pharmaceuticals worth $656K as of Q2 2026.
Park Avenue Securities sold 616 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $186K.
Alnylam Pharmaceuticals made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1164 holding.
Park Avenue Securities first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Park Avenue Securities's Alnylam Pharmaceuticals position peaked at $1.25M in Q3 2025.
149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.